Technical Data
T9160-15R
Tumor Necrosis Factor alpha, Recombinant, Human (TNF-alpha, TNFA, TNF-a, Cachectin, DIF, Tumor Necrosis Factor, TNF, Tumor Necrosis Factor Ligand Superfamily Member 2, TNFSF2)
10ug
|
Technical Data |
|
T9160-15R |
Tumor Necrosis Factor alpha, Recombinant, Human (TNF-alpha, TNFA, TNF-a, Cachectin, DIF, Tumor Necrosis Factor, TNF, Tumor Necrosis Factor Ligand Superfamily Member 2, TNFSF2) |
10ug |
| Growth Factors, Cytokines | Storage: -20°CShipping: Blue Ice |
|
Source: Recombinant corresponding to 158aa of human Tumor Necrosis Factor-alpha expressed in E.coli is a single, non-glycosylated, polypeptide chain. Molecular Weight: ~17.5kD Biological Activity: The ED50 as determined by the cytolysis of mouse L929 cells in the presence of Actinomycin D is less then 0.05ng/ml, corresponding to a Specific Activity of 2x107IU/mg. Dimmers and Aggregates: 1% (SDS-PAGE) Protein Content: Protein quantitation was carried out by two independent methods: 1. UV spectroscopy at 280nm using the absorbency value of 1.24 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). 2. Analysis by RP-HPLC, using a calibrated solution of TNF-alpha as a Reference Standard. Storage and Stability: Lyophilized powder may be stored at -20°C. Stable for 12 months at -20°C. Reconstitute with sterile ddH2O, HSA or BSA. Aliquot to avoid repeated freezing and thawing. Store at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer. Molecular Weight: ~17.5kD |
Purity: ~98% (RP-HPLC, Anion-exchange FPLC, SDS-PAGE) Endotoxin: 0.1ng/ug (IEU/ug) Concentration: Not determined Form: Supplied as a lyophilized powder. No preservative added. Reconstitute with sterile dH2O, 0.1% HSA or BSA to 0.1mg/ml. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological. |
|
1. Translational research on TNF-alpha as an endogenous tumor promoter and green tea as cancer preventive in humans. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2005;23(1):3-30. 2. Small-molecule inhibition of TNF-alpha. Science 2005 Nov 11;310(5750):1022-5. 3. Release of TNF-alpha and IL-1beta from porcine brain endothelium corresponds to the pyrogenic potential of three marketed formulations of amphotericin. Inflamm Res 2005 Sep;54(9):375-9. 4. Roles of TNF-alpha and IgE in the late phase of contact hypersensitivity induced by trimellitic anhydride. Exp Mol Med 2005 Oct 31;37(5):408-17. 5. Cellular cIAP2 gene expression associated with anti-HBV activity of TNF-alpha in hepatoblastoma cells. J Interferon Cytokine Res 2005 Oct;25(10):617-26. 6. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) block ing agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005 Nov;64 Suppl 4:iv2-14.
|
||